Back to Directory

Liraglutide

Metabolic & Weight Management

GLP-1 receptor agonist for diabetes and weight loss, marketed as Victoza and Saxenda.

Key Benefits

  • ✓Moderate weight loss (5-10%)
  • ✓Improved glycemic control
  • ✓Reduced appetite
  • ✓Cardiovascular benefits
  • ✓Lower HbA1c in diabetics
  • ✓Slowed gastric emptying

Dosing Information

Dosage Range
0.6-3.0 mg
Frequency
Once daily
Typical Duration
5 week titration, then ongoing

Detailed Protocol

Administered via subcutaneous injection once daily. Gradual dose escalation over 5 weeks to minimize side effects. Can be injected any time of day with or without food.

About Liraglutide

Liraglutide is a GLP-1 receptor agonist with 97% homology to native human GLP-1. It requires daily injection due to its shorter half-life compared to semaglutide. FDA-approved for type 2 diabetes (Victoza) and weight management (Saxenda at higher dose).

Research Notes

LEADER trial demonstrated cardiovascular benefits in type 2 diabetes patients. SCALE trials showed weight loss efficacy. First GLP-1 RA approved for weight management.

Get Peptide Research Updates

Newsletter signup

Please wait...

Thanks for signing up! You will receive an email to confirm your subscription.

Potential Side Effects

  • •Nausea
  • •Diarrhea
  • •Constipation
  • •Headache
  • •Vomiting
  • •Possible pancreatitis risk

Always consult with a healthcare professional before starting any peptide therapy.